Post-translational modifications in bladder cancer: Expanding the tumor target repertoire.
Options
BORIS DOI
Date of Publication
October 17, 2018
Publication Type
Article
Division/Institute
Author
Oo, Htoo Zarni | |
Black, Peter C | |
Daugaard, Mads |
Subject(s)
Series
Urologic oncology - seminars and original investigations
ISSN or ISBN (if monograph)
1078-1439
Publisher
Elsevier
Language
English
Publisher DOI
PubMed ID
30342880
Uncontrolled Keywords
Description
Over the past decade, genomic and transcriptomic analyses have uncovered promising tumor antigens including immunotherapeutic targets in bladder cancer (BCa). Conventional tumor antigens are proteins expressed on the plasma membrane of tumor cells such as EGFR, FGFR3, and ERBB2 in BCa, which can be targeted by antibodies or similar epitope-specific binding reagents. The cellular proteome consists of ∼100,000 proteins but the expression of these proteins is rarely unique to tumor cells. Many tumor-associated proteins are post-translationally modified with phosphorylation, glycosylation, ubiquitination, or SUMOylation moieties. Although these modifications expand the complexity, they potentially offer novel targeting opportunities across tumor sub-populations. Experimental targeting of cancer-specific post-translational modifications (PTMs) has shown encouraging results in pre-clinical models of BCa, which could potentially overcome issues with inherent intra-tumor heterogeneity due to simultaneous expression on different proteins. Here, we review current knowledge on post-translational modifications in BCa and highlight recent efforts in experimental targeting strategies.
File(s)
File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
---|---|---|---|---|---|---|---|
Se_Post-translational modifications in bladder cancer, Expanding the tumor target repertoire.pdf | text | Adobe PDF | 610.44 KB | publisher | published |